Literature DB >> 517645

Insulin antagonistic effects of epinephrine and glucagon in the dog.

L Saccà, N Eigler, P E Cryer, R S Sherwin.   

Abstract

The effect of glucagon and/or epinephrine on the response to physiologic insulin infusion was evaluated in dogs. Insulin alone produced a transient fall (50%) in glucose output, a threefold rise in glucose clearance, and a decline in plasma glucose, which then stabilized (40--45 mg/dl) afer 1 h. Glucagon infusion prevented the fall in glucose output, but had no effect on insulin-induced elevations in glucose clearance. The fall in plasma glucose was delayed (20 min), but late hypoglycemia was unaltered. Epinephrine infusion blocked the fall in glucose output as well as the insulin-induced rise in glucose clearance and uptake. Thus, while epinephrine and glucagon were equally effective in preventing the fall in glucose output induced by insulin, epinephrine was more effective in preventing insulin-induced hypoglycemia by virtue of its direct inhibitory action on insulin-stimulated glucose utilization. Simultaneous addition of glucagon and epinephrine increased glucose output twofold, suppressed glucose clearance, and caused a 15--30 mg/dl increase in plasma glucose despite ongoing hyperinsulinemia. Our data thus indicate that synergistic hormone interactions may play a role in the counterregulation of insulin hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517645     DOI: 10.1152/ajpendo.1979.237.6.E487

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  The physiological basis of insulin treatment--clinical aspects.

Authors:  W K Waldhäusl
Journal:  Diabetologia       Date:  1986-12       Impact factor: 10.122

2.  Life in the fat lane: seasonal regulation of insulin sensitivity, food intake, and adipose biology in brown bears.

Authors:  K S Rigano; J L Gehring; B D Evans Hutzenbiler; A V Chen; O L Nelson; C A Vella; C T Robbins; H T Jansen
Journal:  J Comp Physiol B       Date:  2016-12-16       Impact factor: 2.200

3.  Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension.

Authors:  G Lembo; R Napoli; B Capaldo; V Rendina; G Iaccarino; M Volpe; B Trimarco; L Saccà
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

4.  Plasma insulin levels and beta-adrenoceptor antagonists. The effects of cardioselective and non-cardioselective beta-adrenoceptor antagonists with and without intrinsic sympathomimetic activity on basal insulin level and insulin level after glucose stimulation in normoglycemic dogs.

Authors:  W Conca; A Beck; S Bacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

Review 5.  Diabetes, insulin and exercise.

Authors:  E A Richter; H Galbo
Journal:  Sports Med       Date:  1986 Jul-Aug       Impact factor: 11.136

6.  Plasma insulin levels and beta-adrenoceptor antagonists. Relevance of the steric configuration of beta-adrenoceptor antagonists to their effect on glucose tolerance.

Authors:  A Beck; W Conca; S Bacher; G Raberger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

7.  Mechanisms of epinephrine-induced glucose intolerance in normal humans.

Authors:  L Saccà; C Vigorito; M Cicala; B Ungaro; R S Sherwin
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

8.  Effects of alpha and beta adrenergic blockade on hepatic glucose balance before and after oral glucose. Role of insulin and glucagon.

Authors:  Z Chap; T Ishida; J Chou; L Michael; C Hartley; M Entman; J B Field
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

9.  Exercise intensity modulation of hepatic lipid metabolism.

Authors:  Fábio S Lira; Luiz C Carnevali; Nelo E Zanchi; Ronaldo Vt Santos; Jean Marc Lavoie; Marília Seelaender
Journal:  J Nutr Metab       Date:  2012-04-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.